Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
MindMaze Therapeutics Holding's Days Inventory for the quarter that ended in Dec. 2025 was 2,043.28.
Inventory Turnover measures how fast the company turns over its inventory within a year.
MindMaze Therapeutics Holding's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.09.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MindMaze Therapeutics Holding's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.89.
MindMaze Therapeutics Holding (XSWX:MMTX) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
MindMaze Therapeutics Holding's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MindMaze Therapeutics Holding's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Change In Inventory Related Terms
MindMaze Therapeutics Holding Change In Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Change In Inventory Chart
MindMaze Therapeutics Holding Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of CHF0.00 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Change In Inventory of CHF0.00 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Change In Inventory too high?
MindMaze Therapeutics Holding's current Change In Inventory is CHF0.00 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Change In Inventory compare to VRTX and REGN?
MindMaze Therapeutics Holding's Change In Inventory of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Change In Inventory is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Change In Inventory of CHF0.00 Mil. The current Change In Inventory is CHF0.00 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Change In Inventory is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
